Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quigley “eezes” into profitability

This article was originally published in The Tan Sheet

Executive Summary

Cold-Eeze marketer will add honey lemon flavor to zinc lozenge line in time for next cold season, firm says Feb. 19. All Cold-Eeze products will be promoted in the fall with six-week radio ad campaign; Quigley says it has shifted emphasis from broad-based media campaigns to more "efficient" programs, to which firm attributes recent strong earnings growth. For the year, Quigley reported revenues up 46.8% to $24.7 mil., with net income of $216,000 compared with a $5.2 mil. loss last year. Q4 revenue rose 19.7% to $8.5 mil.; net income inched up 2.7%...

You may also be interested in...



Quigley sales

Cold-Eeze marketer spent $714,329 on cooperative advertising promotions during third quarter ended Sept. 30, more than triple the level spent in the year-ago period, 1Quigley's 10-Q says. Net sales rose 19.2% to $8.3 mil., with a net loss of $500,395, compared to net income of $313,615 in the year-ago period. Quigley is partnering with CDC to include educational materials about appropriate antibiotic use in Cold-Eeze samples sent to 7,000-8,000 healthcare providers by year end. Firm also intends to introduce one Cold-Eeze line extension in March 2003; honey lemon-flavored zinc lozenge, the line's most recent addition, began shipping in August (2"The Tan Sheet" Feb. 25, 2002, In Brief)...

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS093672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel